newsfilter
← Latest News
Business Wire·

Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

  • Tvardi Therapeutics, Inc. (NASDAQ: TVRD) will participate in the Piper Sandler 37th Annual Healthcare Conference held December 2-4, 2025, in New York, NY.
  • Management will host a fireside chat on Tuesday, December 2, 2025, at 12:00 PM ET.
  • The fireside chat webcast will be accessible on Tvardi's Investors' website with a replay available for approximately 90 days post-conference.
  • Tvardi is a clinical-stage biopharmaceutical company developing oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases.
  • STAT3 is identified as a central mediator in fibrotic signaling pathways and a key factor in cancer cell survival & immune evasion.
  • The company is conducting clinical trials for TTI-101 in hepatocellular carcinoma (NCT05440708) & TTI-109 in healthy volunteers.
  • Investor relations contact is PJ Kelleher at LifeSci Advisors (pkelleher@lifesciadvisors.com).